Saint-Laurent du Var, France, September 3, 2019 – Horus Pharma, an independent laboratory specialized in ophthalmology, announces today the launch of a new 15ml bottle of Neovis Total Multi for the French, Belgian and Spanish markets. The product is prescribed as third-line therapy for the treatment of dry eyes with keratitis or dry keratoconjunctivitis, following unsuccessful treatment with low-viscosity tear substitutes and gels.

 

Neovis Total Multi is an artificial tear emulsion that acts on the entire tear film, including the lipid layer. Preservative and surfactant free, it increases the thickness of the tear film and has both anti-inflammatory and antioxidant effects.

 

The new bottle is fitted with a silicone membrane nozzle, which prevents microbial contamination of the emulsion, while also keeping it sterile. It can be used for four months after opening, which is equivalent to the average length of treatment. Neovis Total Multi is also marketed in a 10ml bottle in France, Belgium and Spain.

 

Dry eyes is a disorder of the tear film due to the deficiency or excessive evaporation of tears. This can lead to ocular surface changes in the area of the palpebral fissure and may be accompanied by symptoms of ocular discomfort.

 

The symptoms of dry eye syndrome can include pain, itching, foreign body sensation, burning, photophobia and general discomfort. Regardless of its etiology, dry eye may cause keratitis and/or conjunctivitis.

 

According to the European Dry Eye Network, approximately 30% of patients seeking ophthalmological treatment in the developed countries have symptoms consistent with the dry eye disease (DED). Epidemiological reviews estimate prevalence of DED at 5-35 % (variation attributed to diagnostic methods, geography, age, and sex). An estimated 50% of people over 75 are affected.

 

“We are pleased with the launch of Neovis Total Multi 15ml, as it broadens the therapeutic arsenal for the symptomatic treatment of dry eye in a new-sized bottle more suited to the pathology,” said Martine Claret, president of Horus Pharma.

 

Neovis Total Multi 15ml has been marketed in France since February 2019, on prescription by ophthalmologists. Horus Pharma obtained the reimbursement of this class IIb medical device by the French Social Security system. It was granted by the Economic Committee of Health Care Products (Comité Economique des Produits de Santé, CEPS) on January 25, 2019.

 

The new 15ml bottle of Neovis Total Multi was launched in Spain in January 2019 and in Belgium in May 2019.

 

The opinion of the French National Authority for Health on Neovis Total Multi 15ml can be viewed here. (FR)

 

About Horus Pharma

Horus Pharma is an independent ophthalmology laboratory that develops, patents and markets preservative-free health products for eyes and eyelids. The company comprehensively addresses patients’ needs by offering more than fifty subsidized and non-subsidized products for ophthalmology, dermo-ophthalmology, contactology, ocular micronutrition and surgery.

Horus Pharma is among the market leaders in France in its sector. It maintains a strong focus on innovation, by investing 10 percent of its turnover into R&D.

The company distributes its products in France and worldwide through its subsidiaries in Spain, the Netherlands, Belgium and Luxembourg, and through distribution agreements in other countries.

Founded in 2003 in Saint-Laurent du Var, France, by Martine and Claude Claret, Horus Pharma currently has more than 140 employees. In 2018 its turnover was €50 million ($56.5M). The company works closely with France’s Vision Institute, the National Institute of Agricultural Research (INRA), the National Center for Scientific Research (CNRS) and the Universities of Paris and Marseille. It is a member of the Eurobiomed cluster and collaborates with numerous European universities and companies.

www.horus-pharma.com/gb www.horus-epharma.fr